Coya Therapeutics (NASDAQ:COYA) Releases Quarterly Earnings Results, Misses Estimates By $0.10 EPS

Coya Therapeutics (NASDAQ:COYA) posted its quarterly earnings data on Tuesday. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10), FiscalAI reports. Coya Therapeutics had a negative return on equity of 52.05% and a negative net margin of 270.22%. The firm had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.11 million.

Coya Therapeutics Stock Performance

Shares of Coya Therapeutics stock traded up $0.03 during midday trading on Tuesday, reaching $3.36. 33,871 shares of the company’s stock traded hands, compared to its average volume of 178,726. The company has a market cap of $78.83 million, a price-to-earnings ratio of -3.14 and a beta of 0.70. The company’s 50 day simple moving average is $4.40 and its 200 day simple moving average is $4.61. Coya Therapeutics has a 52 week low of $2.72 and a 52 week high of $6.62.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Chardan Capital reiterated a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research report on Wednesday, August 12th. BTIG Research restated a “buy” rating and set a $16.00 price objective on shares of Coya Therapeutics in a report on Tuesday, September 15th. HC Wainwright restated a “buy” rating on shares of Coya Therapeutics in a report on Friday, September 25th. Roth Capital reaffirmed a “buy” rating and set a $12.00 price objective on shares of Coya Therapeutics in a research note on Monday, August 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a report on Thursday, October 15th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $15.00.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. Tregs help regulate immune activity, and the company is studying their potential to address neurodegenerative diseases and other conditions involving inflammation and immune dysfunction.

The company’s lead investigational program, COYA 101, is an autologous Treg cell therapy being evaluated for amyotrophic lateral sclerosis (ALS). The treatment is designed to use a patient’s own regulatory T cells, which are expanded and functionally enhanced outside the body before being administered.